Literature DB >> 19450686

Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock.

Tsukasa Nakamura1, Eiichi Sato, Nobuharu Fujiwara, Yasuhiro Kawagoe, Tsukasa Suzuki, Yoshihiko Ueda, Shingo Yamada, Hisataka Shoji, Masayoshi Takeuchi, Seiji Ueda, Takanori Matsui, Hisashi Adachi, Seiya Okuda, Sho-ichi Yamagishi.   

Abstract

There is a growing body of evidence that nitric oxide (NO) excess plays a central role in the pathogenesis of hypotension and organ failure in patients with septic shock. In addition, recently, asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, has been shown to contribute to the regulation of vascular tone via modulation of NO generation in vivo. However, the kinetics and regulation of serum levels of ADMA in patients with septic shock are largely unknown. Since high mobility group box 1 (HMGB1)-receptor for advanced end products (RAGE) axis is supposed to be involved in the lethality in septic shock, we examined the correlations among serum levels of ADMA, endotoxin, interleukin-6 (IL-6), soluble form of RAGE (sRAGE) and RAGE ligands such as HMGB1 and advanced glycation end products (AGE) in septic shock patients. Fifteen septic shock patients (10 males and 15 females, mean age: 70.1+/-8.5 years) and fifteen age- and sex-matched healthy volunteers were included in this study. The criteria of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference were used for diagnosis of septic shock. All the subjects underwent a complete history and physical examination, determination of blood chemistries, including serum levels of ADMA, endotoxin, IL-6, HMGB1, AGE and sRAGE. Linear and multiple stepwise regression analysis were performed for the determinants of serum levels of ADMA. Serum levels of ADMA were significantly higher than those in healthy volunteers (0.98+/-0.21nmol/mL vs. 0.30+/-0.05nmol/mL, p<0.0001). In univariate analysis, creatinine (p<0.005), endotoxin (p<0.001), IL-6 (p<0.001), HMGB1 (p<0.001), AGE (p<0.001) and sRAGE (p<0.001) were significantly associated with serum ADMA levels. After performing multivariate stepwise regression analyses, IL-6 (p=0.001), AGE (p=0.002) and creatinine (p=0.013) still remained significant independently. The present study is the first demonstration that ADMA levels were significantly elevated in patients with septic shock and that serum IL-6, AGE and creatinine levels were independent determinants of ADMA in these patients. Given the harmful effects of NO excess in septic shock, ADMA levels may be increased as a counter-system against inflammation and oxidative stress in this life-threatening disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450686     DOI: 10.1016/j.phrs.2009.05.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  22 in total

Review 1.  A synopsis on aging-Theories, mechanisms and future prospects.

Authors:  João Pinto da Costa; Rui Vitorino; Gustavo M Silva; Christine Vogel; Armando C Duarte; Teresa Rocha-Santos
Journal:  Ageing Res Rev       Date:  2016-06-25       Impact factor: 10.895

2.  Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2016-03-10

3.  Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis.

Authors:  Jin-Cheng Zeng; Wen-Yu Xiang; Dong-Zi Lin; Jun-Ai Zhang; Gan-Bin Liu; Bin Kong; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Lai-Long Yi; Ji-Xin Zhong; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Increased circulating advanced glycation endproducts (AGEs) in acute trauma patients.

Authors:  Carl I Schulman; Jaime Uribarri; Weijing Cai; Ron Manning; David C Landy; Margaret Gallardo; Angela Castillo; Nicholas Namias; Gary E Striker; Alan Livingstone; Helen Vlassara
Journal:  Clin Chem Lab Med       Date:  2014-01-01       Impact factor: 3.694

5.  Pyrosequencing of Mytilus galloprovincialis cDNAs: tissue-specific expression patterns.

Authors:  John A Craft; Jack A Gilbert; Ben Temperton; Kate E Dempsey; Kevin Ashelford; Bela Tiwari; Tom H Hutchinson; J Kevin Chipman
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

Review 6.  Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Authors:  Usama Elewa; Maria Dolores Sanchez-Niño; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

7.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

8.  Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients.

Authors:  Hideyuki Hyogo; Sho-Ichi Yamagishi; Sayaka Maeda; Kei Fukami; Seiji Ueda; Seiya Okuda; Takashi Nakahara; Yuki Kimura; Tomokazu Ishitobi; Kazuaki Chayama
Journal:  Clin Exp Med       Date:  2012-11-23       Impact factor: 3.984

9.  Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma.

Authors:  Ling Zeng; An-qiang Zhang; Wei Gu; Jian Zhou; Lian-yang Zhang; Ding-yuan Du; Mao Zhang; Hai-yan Wang; Jun Yan; Ce Yang; Jian-xin Jiang
Journal:  Crit Care       Date:  2012-07-24       Impact factor: 9.097

10.  Association of dimethylarginines and mediators of inflammation after acute ischemic stroke.

Authors:  Shufen Chen; Jens Martens-Lobenhoffer; Karin Weissenborn; Jan T Kielstein; Ralf Lichtinghagen; Milani Deb; Na Li; Anita B Tryc; Annemarie Goldbecker; Qiang Dong; Stefanie M Bode-Böger; Hans Worthmann
Journal:  J Neuroinflammation       Date:  2012-11-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.